Major Depressive Disorder

The investigational antidepressant ALTO-300 demonstrated clinically meaningful improvements in patients with major depressive disorder, particularly among those characterized by a biomarker, according to a manufacturer press release.

A potential next-generation lithium treatment is set to be tested in major depressive disorder after the FDA issued a “study may proceed” letter for a phase 2a trial of AL001 by Alzamend Neuro.

A single dose of Cybin Inc.’s CYB003, an investigational deuterated psilocybin analog, resulted in statistically significant improvement in depression symptoms after 3 weeks compared with placebo, the company announced in a press release.

Brilaroxazine, a potential new treatment for schizophrenia, significantly improved symptoms and was well-tolerated in a pivotal phase 3 trial, according to a press release from its manufacturer.

Ajovy significantly reduced depression symptoms and monthly migraine days in a phase 4 study, with clinically meaningful improvements in disability outcomes, manufacturer Teva Pharmaceuticals announced in a press release.

A Manhattan-based biopharmaceutical firm has announced positive topline data from its phase 2 trial of a novel formulation of intranasal racemic ketamine for acute suicidal ideation and behavior in adults with major depressive disorder.

Brain-based biomarkers of likely drug response were associated with a greater mean reduction in reported PTSD symptoms in a study of patients treated with ALTO-100.

The FDA has approved Exxua, an oral selective 5HT1a receptor agonist for the treatment of major depressive disorder in adults.

A single dose of psilocybin resulted in clinically and statistically significant reductions in depressive symptoms and functional disability compared with placebo in patients with major depressive disorder, according to a phase 2 study.

Suicidal behavior was associated with more than twice the risk for all-cause mortality in patients with major depressive disorder, as well as increased work loss and health care resource utilization, according to a Swedish study.